Supernus Pharmaceuticals, Inc. stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideToo few of the required measures on file
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWeak
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its Evidence strength.
Discovery Gap: Very high (83/100) · Gap confidence 64/100
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideStrong 64/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideModerate 41/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Evidence timeline
- Expected
Tue 2 Mar · expected 10-K
Last year filed 2 Mar 2026.
Wed 5 May · expected 10-Q
Last year filed 5 May 2026.
- Filed
Mon 2 Nov · 8-K
8-K · Item 3.01 — Listing notice
Recognition: Balanced 61 → Balanced 57Gap Very high · 64 → Very high · 83Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Mon 2 Nov · 8-K
8-K · Items 1.01, 2.01, 2.03, 3.03, 5.01 — Material agreement
Supernus Pharmaceuticals completed merger with Indivior Pharmaceuticals on November 2, 2026, creating a diversified CNS biopharmaceutical leader with 11-product portfolio, enhanced scale, and improved financial flexibility. Combined entity operates as Supernus, Inc.
Recognition: Balanced 61 → Balanced 57Gap Very high · 64 → Very high · 83Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Thu 29 Oct · 8-K
8-K · Item 2.02 — Results of operations
Q3 2026 record revenues of $226.8M (+18% YoY); growth products up 29%. ONAPGO received orphan-drug exclusivity; sNDA submitted for second supplier. Indivior merger expected to close November 2, 2026, creating diversified CNS leader with $125M annual cost synergies.
News flow: Balanced 54 → Balanced 51Gap Very high · 62 → Medium · 16The filings read less positively.
The gap narrowed as the filings read less positively.
The price trend strengthened.
Thu 29 Oct · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
News flow: Balanced 54 → Balanced 51Gap Very high · 62 → Medium · 16The filings read less positively.
The gap narrowed as the filings read less positively.
The price trend strengthened.
Mon 26 Oct · 8-K
8-K · Item 1.02 — Material agreement terminated
Gap Very high · 64 → Very high · 61The gap narrowed — attention is catching up.
Thu 22 Oct · 8-K
8-K · Item 8.01 — Other events
Gap Very high · 60 → Very high · 50The gap narrowed — attention is catching up.
Mon 19 Oct · 8-K
8-K · Item 2.02 — Results of operations
Supernus announced it will report Q3 2026 results on October 29, 2026 after market close, with a conference call at 4:30 p.m. E.T. This is a routine earnings release notification.
Recognition: Balanced 55 → Balanced 58Gap Very high · 64 → Very high · 60The gap narrowed — attention is catching up.
Thu 15 Oct · 8-K
Gap Very high · 64 → Very high · 61The gap narrowed — attention is catching up.
Mon 3 Aug · 8-K
Mon 3 Aug · 8-K
Mon 3 Aug · 10-Q
Quarterly report (10-Q), period ending 28 Jul 2026
Mon 3 Aug · 8-K
Mon 3 Aug · 8-K
Wed 22 Jul · 8-K
Thu 18 Jun · 8-K
Wed 20 May · 8-K
Tue 5 May · 10-Q
Quarterly report (10-Q), period ending 28 Apr 2026
Tue 5 May · 8-K
Wed 22 Apr · 8-K
Tue 7 Apr · 8-K
Mon 2 Mar · 10-K
Annual report (10-K), FY2026
Tue 24 Feb · 8-K
Tue 24 Feb · 8-K
Thu 12 Feb · 8-K
Wed 28 Jan · 8-K
Thu 6 Nov · 10-Q
Quarterly report (10-Q), period ending 29 Oct 2025
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.